ClinicalTrials.gg
CompletedNCT02616614Updated May 27, 2020Results posted

Double-blind Placebo-controlled Trial of Generic Clindamycin/Benzoyl Peroxide Gel Versus Onexton Gel in Acne Vulgaris

A Phase 3 interventional study of Onexton and Clindamycin/benzoyl peroxide gel in Acne Vulgaris, sponsored by Actavis Inc.. Completed at 17 sites in United States. Open to participants aged 12 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-05-27.

Sponsored by Actavis Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
862
Allocation
Randomized
Ages
12 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing clindamycin in Acne Vulgaris — 1 open to participants now, 2 under way, none of them phase 3. Clindamycin · Acne Vulgaris.

Enrollment
8th of 34
862 · median 117
Started
2015
with 4 others
Phase 3
9 of 34
none open now
Registered
30th of 34
by date
Lead sponsor
1 of 34
Actavis Inc.

Among the 34 studies testing clindamycin in Acne Vulgaris, this one is the 8th largest by enrollment, is one of 5 that started in 2015, is one of 9 in phase 3, and was the 30th registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

1 of the 34 studies testing clindamycin in Acne Vulgaris is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About clindamycin

Clindamycin: first FDA approval 1970 (CLEOCIN HYDROCHLORIDE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 12 Years to 40 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing clindamycin in Acne Vulgaris, or all of them as a file.
02

Study summary

Actavis has developed a generic formulation of clindamycin 1.2% and benzoyl peroxide 3.75% gel. This study is designed to evaluate the safety and efficacy of this formulation in subjects with Acne Vulgaris

Read the detailed description

This is a randomized, double blind, three-arm, parallel group, placebo control bioequivalence study with clinical endpoint, at multiple study sites, designed to establish bioequivalence of clindamycin 1.2% and benzoyl peroxide 3.75% gel of Actavis and Onexton® (clindamycin 1.2% and benzoyl peroxide 3.75%) gel in the treatment of subjects with Acne Vulgaris.

The primary objective is to evaluate the bioequivalence of a generic of clindamycin 1.2% and benzoyl peroxide 3.75% gel to Onexton® in the treatment of subjects with acne vulgaris.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

04

Who can participate

Ages eligible
12 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or non-pregnant female aged ≥ 12 and ≤ 40 years with a clinical diagnosis of acne vulgaris
  • On the face, ≥25 non-inflammatory lesions (i.e., open and closed comedones) and ≥ 20 inflammatory lesions (i.e., papules and pustules) and ≤ 2 nodulocystic lesions (i.e., nodules and cysts). For the purposes of study treatment and evaluation, these lesions should be limited to the facial treatment area. Counts of nodules and cysts should be reported separately and not included in the inflammatory or non-inflammatory lesion counts. Lesions involving the eyes and scalp should be excluded from the count. (Subjects may have acne lesions on other areas of the body (e.g., on the back)).
  • Subjects must have Investigator's Global Assessment (IGA) of acne severity grade 2, 3, or 4.
  • Willing to refrain from use of all other topical acne medications or antibiotics during the 12 week treatment period. Subjects may use other topical acne treatments that do not have significant or measurable systemic absorption for treatment of acne of the back, shoulders and chest (e.g. benzoyl peroxide, salicylic acid).
  • Subjects who are 18 years of age or older must have provided Institutional Review Board (IRB) approved written . Subjects who are at least 12 years of age and less than 18 years of age must have provided IRB approved written assent; this written assent must be accompanied by an IRB approved written informed consent from the subject's legally acceptable representative (i.e., parent or guardian). In addition, all subjects or their legally acceptable representatives (i.e., parent or guardian) must sign a Health Insurance Portability and Accountability Act (HIPAA) authorization, if applicable.
  • Male subjects and Female subjects of must use accepted methods of or must agree to practice abstinence, from study start to 30 days after the last administration of study drug. All female subjects are considered to be of childbearing potential unless they have been surgically sterilized or have been for at least 1 year. Any of the following methods of birth control are acceptable: oral contraceptives, contraceptive patches/implants (e.g., Norplant®), vaginal ring (NuvaRing®), Depo-Provera® (Medroxy progesterone acetate), double barrier methods (e.g., condom and spermicide) or intrauterine device (IUD).
  • Female subjects of child bearing potential must have a negative urine pregnancy test at baseline.
  • Subjects who use make-up must have used the same brands/types of make-up for a minimum period of 14 days prior to study entry and must agree to not change make-up brand/type or frequency of use throughout the study.

Exclusion criteria

Exclusion Criteria:

  • History of or allergy to clindamycin or benzoyl peroxide and/or any of the study medication ingredients or lincomycin or any other allowed product used during the study.
  • Presence of any skin condition that would interfere with the diagnosis or assessment of acne vulgaris (e.g., on the face: rosacea, dermatitis, psoriasis, squamous cell carcinoma, eczema, acneform eruptions caused by medications, acne, steroid folliculitis, or bacterial folliculitis).
  • Excessive facial hair (beards, sideburns, moustaches, etc.) that would interfere with diagnosis or assessment of acne vulgaris. Patient is allowed to shave the excessive facial hair at least a day before visiting the site for study assessments.
  • Use within 6 months prior to baseline of oral retinoids (e.g. Accutane®) or therapeutic vitamin A supplements of greater than 10,000 units/day.
  • Use for less than 3 months prior to baseline of estrogens or oral ; use of such therapy must remain constant throughout the study.
  • Use on the face within 1 month prior to baseline or during the study of: 1) cryodestruction, 2) dermabrasion, 3) photodynamic therapy, 4) acne surgery, 5) intralesional steroids, or 6) x-ray therapy.
  • Use within 1 month prior to baseline of: 1) spironolactone, 2) systemic steroids, 3) systemic antibiotics, 4) systemic treatment for acne vulgaris or 5) systemic anti-inflammatory agents.
  • Use within 2 weeks prior to baseline of: 1) topical steroids, 2) topical retinoids, 3) topical acne treatments including over-the-counter preparations, 4) topical anti- inflammatory agents, 5) medicated cleansers or 6) topical antibiotics.
  • Subjects who have acne fulminans, and secondary acne (e.g., chloracne and drug induced acne) will be excluded from participation.
  • Female subjects who are pregnant, nursing or planning to become pregnant during study participation (Visit 1 through Visit 4 and 30 days post visit 4) will be excluded from study participation.
  • Subjects who have received radiation therapy and/or anti-neoplastic agents within 90 days prior to baseline will be excluded from study participation.
  • Subjects who have unstable medical disorders that are or life-threatening diseases will be excluded from study participation.
  • Subjects who have on-going requiring systemic treatment will be excluded from study participation. In addition, subjects who have any malignancy of the skin of the facial area will be excluded from study participation.
  • Subjects who engage in activities that involve excessive or prolonged exposure to sunlight or weather extremes, such as wind or cold, will be excluded from study participation.
  • Subjects who have facial sunburn will be excluded from study participation
  • Subjects who consume excessive amounts of alcohol (greater than two drinks per day) or use drugs of abuse (including, but not limited to, cannabinoids and cocaine) as judged by their medical history will be excluded from study participation.
  • History or presence of significant smoking (more than 10 cigarettes or any other form of tobacco smoking/day or consumption of tobacco products).
  • Systolic blood pressure less than 90 mm Hg or more than 140 mm Hg, Diastolic blood pressure less than 60 mm Hg or more than 90 mm Hg and Pulse rate less than 50 beats/minute or more than 100 beats/minute.
  • Subjects who have participated in an drug study (i.e., subjects have been treated with an investigational drug) within 1 month prior to baseline will be excluded from study participation. Subjects who are participating in non- treatment studies such as observational studies or registry studies can be considered for inclusion.
  • Major illness, as per investigator's discretion, during 3 months before screening.
  • Subjects who have been previously enrolled in this study will be excluded from study participation.
  • Subjects who have had laser therapy and electrodesiccation to the facial area within 180 days prior to study entry will be excluded from participation.
  • Subjects who have had cosmetic procedures (e.g., facials) which may affect the efficacy and safety profile of the investigational product within 14 days prior to study entry will be excluded from participation.
  • Subjects who have had general anesthesia for any reason and subjects who have received neuromuscular blocking agents within 14 days prior to study entry will be excluded from study participation.
  • Subjects who have a baseline score of 3 (severe, marked/intense) as per the Application Site Reaction Scale (Section 5.2) will be excluded from participation.
  • Any employees or staff of the research site are excluded from study participation.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
862 participants (actual)

Study arms

  • Active comparator
    Onexton gel

    Clindamycin 1.2% and benzoyl peroxide 3.75% topical gel Applied a thin film of medication onto 6 areas of the face (chin, left cheek, right cheek, nose, left forehead, and right forehead) once daily

    Drug: Onexton

  • Experimental
    Clindamycin/benzoyl peroxide gel

    Generic clindamycin 1.2% and benzoyl peroxide 3.75% topical gel. Applied a thin film of medication onto 6 areas of the face (chin, left cheek, right cheek, nose, left forehead, and right forehead) once daily

    Drug: Clindamycin/benzoyl peroxide gel

  • Placebo comparator
    Placebo

    A vehicle gel. Applied a thin film of medication onto 6 areas of the face (chin, left cheek, right cheek, nose, left forehead, and right forehead) once daily

    Drug: Placebo

Interventions

  • DrugOnexton

    Drug pages: Clindamycin · Benzoyl Peroxide

    Topical gel for treating acne

    Also known as: Clindamycin/benzoyl peroxide gel

  • DrugClindamycin/benzoyl peroxide gel

    Drug pages: Clindamycin · Benzoyl Peroxide

    Generic Clindamycin/benzoyl peroxide gel for treating acne

    Also known as: Clindamcyin Phosphate, BPO

  • DrugPlacebo

    Vehicle gel used as a placebo

    Also known as: Vehicle

06

What researchers measure

Primary outcomes

  1. Percent Change in the Inflammatory (Papules and Pustules) Lesion Counts

    Percent change from baseline to Week 12 (Day 84) in the inflammatory (papules and pustules) lesion count in PP Population.

    Time frame: 12 weeks

  2. Percent Change in the Non-Inflammatory (Open and Closed Comedomes) Lesion Counts

    One of the co-primary endpoints was the percent change from baseline to Week 12 (Day 84) in the non-inflammatory (open and closed comedones) lesion counts in PP Population.

    Time frame: 12 weeks

Secondary outcomes

  1. Number of Subjects With Treatment Success at Week 12

    The secondary efficacy endpoint was the IGA score, expressed in terms of proportion of subjects with treatment success or failure at Week 12, where "success" was defined as an IGA score that was at least 2 grades less than the baseline assessment.

    Time frame: 12 weeks

07

Results

Posted May 27, 2020

Participant flow

Participant flow — Overall Study
MilestoneGeneric Clindamycin 1.2% and Benzoyl Peroxide 3.75% GelOnexton (Clindamycin 1.2% and Benzoyl Peroxide 3.75% Gel)Vehicle Gel
Started347345170
Safety population329328161
Mitt population325325160
Pp population253255122
Completed282285141
Not completed656029
Withdrew: Withdrawal by subject1056
Withdrew: Physician decision210
Withdrew: Adverse event141
Withdrew: Protocol violation031
Withdrew: Prohibited medication1295
Withdrew: More than 3 applications missed681
Withdrew: Lost to follow-up312813
Withdrew: Pregnancy201
Withdrew: Other121

Outcome measures

PrimaryPercent Change in the Inflammatory (Papules and Pustules) Lesion Counts

Percent change from baseline to Week 12 (Day 84) in the inflammatory (papules and pustules) lesion count in PP Population.

Time frame:
12 weeks
Reported as:
Mean · percentage of change
Percent Change in the Inflammatory (Papules and Pustules) Lesion Counts
percentage of changeGeneric Clindamycin and Benzoyl PeroxideReference Onexton (Clindamycin and Benzoyl Peroxide)Vehicle Gel
Percent Change in the Inflammatory (Papules and Pustules) Lesion Counts-63.81 ± 36.791-67.56 ± 28.405-53.78 ± 40.138
Statistical analysis
  • Generic Clindamycin and Benzoyl Peroxide vs Reference Onexton (Clindamycin and Benzoyl Peroxide) · Mean difference (net): 0.95 · 90% CI 0.88 to 1.03
  • Generic Clindamycin and Benzoyl Peroxide · ANOVA · p = 0.0001
  • Reference Onexton (Clindamycin and Benzoyl Peroxide) · ANOVA · p = <0.0001
PrimaryPercent Change in the Non-Inflammatory (Open and Closed Comedomes) Lesion Counts

One of the co-primary endpoints was the percent change from baseline to Week 12 (Day 84) in the non-inflammatory (open and closed comedones) lesion counts in PP Population.

Time frame:
12 weeks
Reported as:
Mean · percentage of change
Percent Change in the Non-Inflammatory (Open and Closed Comedomes) Lesion Counts
percentage of changeGeneric Clindamycin and Benzoyl PeroxideReference Onexton (Clindamycin and Benzoyl Peroxide)Vehicle Gel
Percent Change in the Non-Inflammatory (Open and Closed Comedomes) Lesion Counts-49.58 ± 40.747-49.50 ± 32.872-37.50 ± 40.261
Statistical analysis
  • Generic Clindamycin and Benzoyl Peroxide vs Reference Onexton (Clindamycin and Benzoyl Peroxide) · Mean difference (net): 1.00 · 90% CI 0.90 to 1.11
  • Generic Clindamycin and Benzoyl Peroxide · ANOVA · p = 0.0002
  • Reference Onexton (Clindamycin and Benzoyl Peroxide) · ANOVA · p = 0.0006
SecondaryNumber of Subjects With Treatment Success at Week 12

The secondary efficacy endpoint was the IGA score, expressed in terms of proportion of subjects with treatment success or failure at Week 12, where "success" was defined as an IGA score that was at least 2 grades less than the baseline assessment.

Time frame:
12 weeks
Reported as:
Number · participants
Number of Subjects With Treatment Success at Week 12
participantsGeneric Clindamycin and Benzoyl PeroxideReference Onexton (Clindamycin and Benzoyl Peroxide)Vehicle Gel
Success546013
Failure199195109
Statistical analysis
  • Generic Clindamycin and Benzoyl Peroxide vs Reference Onexton (Clindamycin and Benzoyl Peroxide) · Mean difference (net): -0.022 · 90% CI -0.087 to 0.043Equivalence was based on difference in the number of subjects with success. Bioequivalence was established if the 90% CI for the difference was contained within the interval (-0.20, +0.20).

Adverse events

Collected over Baseline to 12 Weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Generic Clindamycin 1.2% and Benzoyl Peroxide 3.75% Gel0/329 (0%)4/329 (1.2%)197/329 (59.9%)
Reference Onexton (Clindamycin 1.2% and Benzoyl Peroxide 3.75)0/328 (0%)0/328 (0%)211/328 (64.3%)
Vehicle Gel0/161 (0%)0/161 (0%)92/161 (57.1%)
Most frequent serious events
Most frequent serious events
EventGeneric Clindamycin 1.2% and Benzoyl Peroxide 3.75% GelReference Onexton (Clindamycin 1.2% and Benzoyl Peroxide 3.75)Vehicle Gel
Bipolar disorderPsychiatric disorders1/3290/3280/161
Cranio-cerebral injuryInjury, poisoning and procedural complications1/3290/3280/161
Abortion spontaneousPregnancy, puerperium and perinatal conditions1/3290/3280/161
Allergy to arthropod stingImmune system disorders1/3290/3280/161
Most frequent other events
Showing 10 of 118
Most frequent other events
EventGeneric Clindamycin 1.2% and Benzoyl Peroxide 3.75% GelReference Onexton (Clindamycin 1.2% and Benzoyl Peroxide 3.75)Vehicle Gel
Dry skinSkin and subcutaneous tissue disorders127/329138/32856/161
PruritusSkin and subcutaneous tissue disorders59/32970/32831/161
ErythemaSkin and subcutaneous tissue disorders55/32958/32831/161
Skin burning sensationSkin and subcutaneous tissue disorders34/32927/32811/161
Skin irritationSkin and subcutaneous tissue disorders17/32923/32810/161
Skin erosionSkin and subcutaneous tissue disorders12/32922/3288/161
AcneSkin and subcutaneous tissue disorders9/3299/32810/161
Facial painGeneral disorders16/32917/3285/161
Application site drynessGeneral disorders11/3299/3282/161
PainGeneral disorders8/3293/3280/161

Baseline characteristics

Age, Continuous
Age, Continuous(years)Generic Clindamycin 1.2% and Benzoyl Peroxide 3.75% GelReference Onexton (Clindamycin 1.2% and Benzoyl Peroxide 3.75)Vehicle GelTotal
Mean20.6 ± 7.5620.4 ± 7.0420.1 ± 6.9220.4 ± 7.23
Sex: Female, Male
Sex: Female, Male(Participants)Generic Clindamycin 1.2% and Benzoyl Peroxide 3.75% GelReference Onexton (Clindamycin 1.2% and Benzoyl Peroxide 3.75)Vehicle GelTotal
Female204217105526
Male12511156292
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Generic Clindamycin 1.2% and Benzoyl Peroxide 3.75% GelReference Onexton (Clindamycin 1.2% and Benzoyl Peroxide 3.75)Vehicle GelTotal
Hispanic or Latino768945210
Not Hispanic or Latino253239116608
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Generic Clindamycin 1.2% and Benzoyl Peroxide 3.75% GelReference Onexton (Clindamycin 1.2% and Benzoyl Peroxide 3.75)Vehicle GelTotal
American Indian or Alaska Native0101
Asian4217
Native Hawaiian or Other Pacific Islander0000
Black or African American828642210
White225224110559
More than one race1815841
Unknown or Not Reported0000
08

Study locations

17 sites
  • Alliance Dermatology
    Phoenix, Arizona 85032, United States
  • Estudy
    Chula Vista, California 91911, United States
  • Estudy
    La Mesa, California 91942, United States
  • Tampa Bay Medical Research
    Clearwater, Florida 33761, United States
  • AMB Research Center
    Miami, Florida 33144, United States
  • Meridian Clinical Research
    Savannah, Georgia 31406, United States
  • Heartland Research Assoc
    Augusta, Kansas 67010, United States
  • Heartland Research Assoc
    Wichita, Kansas 67207, United States
  • Sundance Clinical Research
    Saint Louis, Missouri 63141, United States
  • Meridian Clinical Research
    Norfolk, Nebraska 68701, United States
  • Meridian Clinical Research
    Omaha, Nebraska 68134, United States
  • Dermatology Consulting Services
    High Point, North Carolina 27262, United States
  • Sterling Research Group
    Cincinnati, Ohio 45246, United States
  • Discover Research
    Beaumont, Texas 77701, United States
  • DiscoverResearch Inc
    Bryan, Texas 77802, United States
  • Reseacr Across America
    Dallas, Texas 75234, United States
  • Clinical Research Assoc. of Tidewater
    Norfolk, Virginia 23507, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2015, a primary completion of Oct 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.

Results were first posted in May 2020, 4 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2015
First posted
Nov 30, 2015
Start
May 2015
Primary completionActual
Oct 2015
CompletionActual
Nov 2015
Results first posted
May 27, 2020
Last update
May 27, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02616614
Lead sponsor
Actavis Inc.
Responsible party
Sponsor
First posted
Nov 30, 2015
Start date
May 2015
Primary completion
Oct 2015
Completion
Nov 2015
Results posted
May 27, 2020
Last update
May 27, 2020

Study contacts

Henry lau, PhD
study director · Actavis Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Clindamycin · Benzoyl Peroxide

Start the discussion